JP2022023958A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022023958A5 JP2022023958A5 JP2021178868A JP2021178868A JP2022023958A5 JP 2022023958 A5 JP2022023958 A5 JP 2022023958A5 JP 2021178868 A JP2021178868 A JP 2021178868A JP 2021178868 A JP2021178868 A JP 2021178868A JP 2022023958 A5 JP2022023958 A5 JP 2022023958A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl group
- halogen atom
- hydrogen atom
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020008757 | 2020-01-22 | ||
| JP2020008757 | 2020-01-22 | ||
| PCT/JP2021/002088 WO2021149776A1 (ja) | 2020-01-22 | 2021-01-21 | 抗腫瘍活性を有するアリールアミド誘導体 |
| JP2021536299A JP6971432B1 (ja) | 2020-01-22 | 2021-01-21 | 抗腫瘍活性を有するアリールアミド誘導体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536299A Division JP6971432B1 (ja) | 2020-01-22 | 2021-01-21 | 抗腫瘍活性を有するアリールアミド誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022023958A JP2022023958A (ja) | 2022-02-08 |
| JP2022023958A5 true JP2022023958A5 (https=) | 2024-01-30 |
| JP7693513B2 JP7693513B2 (ja) | 2025-06-17 |
Family
ID=76992539
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536299A Active JP6971432B1 (ja) | 2020-01-22 | 2021-01-21 | 抗腫瘍活性を有するアリールアミド誘導体 |
| JP2021178868A Active JP7693513B2 (ja) | 2020-01-22 | 2021-11-01 | 抗腫瘍活性を有するアリールアミド誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536299A Active JP6971432B1 (ja) | 2020-01-22 | 2021-01-21 | 抗腫瘍活性を有するアリールアミド誘導体 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11964950B2 (https=) |
| EP (2) | EP4725941A1 (https=) |
| JP (2) | JP6971432B1 (https=) |
| KR (2) | KR102473971B1 (https=) |
| CN (1) | CN114929669B (https=) |
| AR (1) | AR121078A1 (https=) |
| AU (1) | AU2021211553A1 (https=) |
| BR (1) | BR112022009518A2 (https=) |
| CA (1) | CA3168788A1 (https=) |
| CL (1) | CL2022001938A1 (https=) |
| CO (1) | CO2022011429A2 (https=) |
| CR (1) | CR20220390A (https=) |
| DK (1) | DK4094804T3 (https=) |
| ES (1) | ES3060503T3 (https=) |
| FI (1) | FI4094804T3 (https=) |
| HR (1) | HRP20260094T1 (https=) |
| IL (1) | IL294916B1 (https=) |
| LT (1) | LT4094804T (https=) |
| MA (1) | MA58427B1 (https=) |
| MX (1) | MX2022008722A (https=) |
| PE (1) | PE20230239A1 (https=) |
| PL (1) | PL4094804T3 (https=) |
| PT (1) | PT4094804T (https=) |
| RS (1) | RS67669B1 (https=) |
| SI (1) | SI4094804T1 (https=) |
| TW (2) | TW202313562A (https=) |
| WO (1) | WO2021149776A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| AU2021206684B2 (en) | 2020-01-10 | 2024-01-18 | Immuneering Corporation | MEK inhibitors and therapeutic uses thereof |
| AR121078A1 (es) | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| JPWO2022018875A1 (https=) * | 2020-07-22 | 2022-01-27 | ||
| AU2021311665A1 (en) * | 2020-07-22 | 2023-03-16 | Chugai Seiyaku Kabushiki Kaisha | Composition containing arylamide derivative |
| WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CA3200814A1 (en) | 2020-12-02 | 2022-06-09 | Alfredo C. Castro | Tead inhibitors and uses thereof |
| CA3205726A1 (en) | 2021-01-25 | 2022-07-28 | Alfredo C. Castro | Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer |
| IL307964A (en) * | 2021-06-09 | 2023-12-01 | Chugai Pharmaceutical Co Ltd | Combined treatment for cancer |
| EP4375273A4 (en) * | 2021-07-21 | 2025-05-21 | Chugai Seiyaku Kabushiki Kaisha | Method for producing arylamide derivative |
| WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| TW202339786A (zh) | 2022-01-21 | 2023-10-16 | 日商中外製藥股份有限公司 | 癌症之治療或預防用醫藥 |
| JP7565132B2 (ja) * | 2022-04-20 | 2024-10-10 | 中外製薬株式会社 | がんの治療又は予防用医薬 |
| CN119421874A (zh) * | 2022-06-30 | 2025-02-11 | 上海喆邺生物科技有限公司 | 一种芳香酰胺类衍生物及其在抗肿瘤药物中的应用 |
| JP2025521928A (ja) * | 2022-07-08 | 2025-07-10 | ネステッド・セラピューティクス・インコーポレイテッド | マイトジェン活性化プロテインキナーゼ（ｍｅｋ）阻害剤 |
| WO2025007811A1 (zh) | 2023-07-06 | 2025-01-09 | 成都华健未来科技有限公司 | 一类芳香酰胺类衍生物及其用途 |
| CN121866244A (zh) | 2023-09-21 | 2026-04-14 | 中外制药株式会社 | 用于生产芳基酰胺衍生物的方法 |
| WO2025146040A1 (zh) * | 2024-01-01 | 2025-07-10 | 华健未来（成都）科技股份有限公司 | 芳香酰肼类衍生物及其医药用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2594720Y2 (ja) | 1993-03-22 | 1999-05-10 | 株式会社アーテックスズキ | 連結式キャビネット |
| TW200520745A (en) | 2003-09-19 | 2005-07-01 | Chugai Pharmaceutical Co Ltd | Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors |
| US7732616B2 (en) * | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| CN1905873A (zh) * | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| TWI361066B (en) | 2004-07-26 | 2012-04-01 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| ES2405785T3 (es) | 2005-05-18 | 2013-06-03 | Array Biopharma Inc. | Inhibidores heterocíclicos de MEK y métodos de uso de los mismos |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| CN101432281B (zh) * | 2006-04-19 | 2013-08-28 | 诺瓦提斯公司 | 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法 |
| US20090082328A1 (en) | 2007-05-11 | 2009-03-26 | Bayer Schering Pharma Aktiengesellschaft | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity |
| CA2720818A1 (en) * | 2008-04-22 | 2009-10-29 | Marion Hitchcock | Substituted phenoxybenzamides |
| US8993630B2 (en) * | 2008-11-10 | 2015-03-31 | Bayer Intellectual Property Gmbh | Substituted sulphonamido phenoxybenzamides |
| JP6075621B2 (ja) | 2010-08-10 | 2017-02-08 | 塩野義製薬株式会社 | 新規複素環誘導体およびそれらを含有する医薬組成物 |
| US20130123255A1 (en) | 2011-11-10 | 2013-05-16 | Chugai Seiyaku Kabushiki Kaisha | Combination of a pi3k inhibitor and a mek inhibitor |
| JP2016034900A (ja) | 2012-11-26 | 2016-03-17 | 中外製薬株式会社 | ５−置換−２−フェニルアミノ−ベンズアミド類の製造方法 |
| WO2014164942A1 (en) | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Dual mek/pi3k inhibitors and therapeutic methods using the same |
| WO2015038417A1 (en) | 2013-09-10 | 2015-03-19 | Asana Biosciences, Llc | Compounds for regulating fak and/or src pathways |
| JP6403172B2 (ja) | 2013-10-25 | 2018-10-10 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用 |
| CN104803996A (zh) | 2014-01-27 | 2015-07-29 | 天津滨江药物研发有限公司 | 作为蛋白激酶抑制剂的氮杂环类化合物及其制备方法 |
| CN105384738B (zh) | 2014-08-21 | 2017-08-29 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| AR121078A1 (es) | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| AU2021311665A1 (en) | 2020-07-22 | 2023-03-16 | Chugai Seiyaku Kabushiki Kaisha | Composition containing arylamide derivative |
-
2021
- 2021-01-20 AR ARP210100120A patent/AR121078A1/es unknown
- 2021-01-21 DK DK21744061.9T patent/DK4094804T3/da active
- 2021-01-21 RS RS20260093A patent/RS67669B1/sr unknown
- 2021-01-21 ES ES21744061T patent/ES3060503T3/es active Active
- 2021-01-21 AU AU2021211553A patent/AU2021211553A1/en active Pending
- 2021-01-21 PL PL21744061.9T patent/PL4094804T3/pl unknown
- 2021-01-21 MA MA58427A patent/MA58427B1/fr unknown
- 2021-01-21 IL IL294916A patent/IL294916B1/en unknown
- 2021-01-21 EP EP25226973.3A patent/EP4725941A1/en active Pending
- 2021-01-21 JP JP2021536299A patent/JP6971432B1/ja active Active
- 2021-01-21 PT PT217440619T patent/PT4094804T/pt unknown
- 2021-01-21 LT LTEPPCT/JP2021/002088T patent/LT4094804T/lt unknown
- 2021-01-21 BR BR112022009518A patent/BR112022009518A2/pt unknown
- 2021-01-21 CR CR20220390A patent/CR20220390A/es unknown
- 2021-01-21 WO PCT/JP2021/002088 patent/WO2021149776A1/ja not_active Ceased
- 2021-01-21 KR KR1020227002880A patent/KR102473971B1/ko active Active
- 2021-01-21 TW TW111146325A patent/TW202313562A/zh unknown
- 2021-01-21 EP EP21744061.9A patent/EP4094804B1/en active Active
- 2021-01-21 CA CA3168788A patent/CA3168788A1/en active Pending
- 2021-01-21 KR KR1020227041183A patent/KR102904379B1/ko active Active
- 2021-01-21 MX MX2022008722A patent/MX2022008722A/es unknown
- 2021-01-21 CN CN202180008024.XA patent/CN114929669B/zh active Active
- 2021-01-21 TW TW110102277A patent/TWI788763B/zh active
- 2021-01-21 FI FIEP21744061.9T patent/FI4094804T3/fi active
- 2021-01-21 SI SI202130384T patent/SI4094804T1/sl unknown
- 2021-01-21 HR HRP20260094TT patent/HRP20260094T1/hr unknown
- 2021-01-21 PE PE2022001439A patent/PE20230239A1/es unknown
- 2021-11-01 JP JP2021178868A patent/JP7693513B2/ja active Active
-
2022
- 2022-07-19 CL CL2022001938A patent/CL2022001938A1/es unknown
- 2022-07-20 US US17/869,226 patent/US11964950B2/en active Active
- 2022-08-12 CO CONC2022/0011429A patent/CO2022011429A2/es unknown
-
2024
- 2024-03-18 US US18/608,369 patent/US20240246922A1/en active Pending